BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mucosis B.V. Starts Clinical Study with its Lead Product, Flugem(TM)


3/21/2011 9:21:23 AM

Groningen, the Netherlands, 21 March 2011 -- Dutch biotechnology company Mucosis B.V. today announced the start of a Phase 1 clinical study with its lead product FluGEM™, a novel improved influenza vaccine for the elderly. It is the first-ever study in man with a vaccine candidate based on Mimopath™, a proprietary platform technology for developing more potent vaccines.

The clinical study will be conducted in conjunction with the Centre for Human Drug Research (CHDR; Leiden, the Netherlands). It is designed to test the safety and tolerability of FluGEM™, as well as the mucosal and systemic immune responses including correlates of protection against influenza viruses. The trial will involve FluGEM™ being administered both as droplets in the nose and by intramuscular injection.

Mucosis has evaluated FluGEM™ for safety and toxicity in well-accepted animal models, and found it to be safe at all doses tested. Moreover, preclinical results show an induction of robust mucosal and systemic immunity and superior protection from an influenza challenge.

“We are very pleased with the on-schedule initiation of this Phase 1 study,” said Govert Schouten, CEO of Mucosis. “This is an important step towards realizing our ambition of taking an improved flu vaccine to the market. In addition, this study will validate Mimopath™ as a platform technology for the development of new vaccines that provide better and broader protection”.

The enrollment of volunteers for the trial has been initiated and immunizations are scheduled to start in the next weeks. The vaccine will be tested in 90 adult and 60 elderly trialists. Interim top- line data from the study are expected to become available before the end of 2011. The clinical study is financially supported by Agentschap NL, an agency of the Dutch Ministry of Economic Affairs, Agriculture and Innovation.

For further information please contact:

Govert Schouten CEO Mucosis B.V. +31 (6) 55320948 govert.schouten@mucosis.com www.mucosis.com



Read at BioSpace.com

   
Influenza
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES